论文部分内容阅读
近日,湖南省长沙市公安局发布消息,历经十个多月的侦办,葛兰素史克(中国)投资有限公司(下简称GSKCI)涉嫌对非国家工作人员行贿、单位行贿、对单位行贿等案已侦查终结,于日前依法移送检察机关审查起诉。据介绍,GSKCI在中国销售的药品大多冠以海外原研药名义,在药品进口前通过转移定价的方式,增高药品报关价格,在将巨额利润预提在境外的基础上,设定高额销售成本用于支撑贿赂
Recently, the Hunan Changsha Public Security Bureau issued a news release. After more than 10 months of investigation, GlaxoSmithKline (China) Investment Co., Ltd. (GSKCI) allegedly paid bribes to non-state workers, bribe units, and bribe the units Has been the end of investigation, in accordance with the law before the transfer of prosecution to prosecute. According to reports, GSKCI most of the drugs sold in China under the name of the original overseas drug research, before the import of drugs through transfer pricing approach, increasing the price of drug declarations, the huge profits accrued overseas based on the set of high cost of sales Used to support bribery